The rare disease pharmaceutical sector is experiencing significant growth, with Maple Syrup Urine Disease (MSUD) representing a critical area of therapeutic development. This metabolic disorder, affecting the body's ability to process specific amino acids, presents complex management challenges that have attracted substantial attention from biotechnology companies and medical researchers...
English
العربية
Français
Español
Português
Deutsch
Türkçe
Nederlands
Italiano
Русский
Română
Português
Ελληνικά